Features of cytokine production, subpopulation structure of lymphocytes and functional state of neutrophils in patients with disseminated MDR tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 588s Year: 2006
Increased activation and oligoclonality within peripheral CD8+ T lymphocytes in mycobacterium tuberculosis infected patients Source: Eur Respir J 2004; 24: Suppl. 48, 284s Year: 2004
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003
Lipid profile in patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 361s Year: 2002
Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Dependending on drug resistance character of bacteriostatic blood activity at time polychemotherapy against of M. tuberculosis strains isolated from patients Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002
Lymphocyte subgroups and human leukocyte antigens in multidrug resistant and smear positive tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 645s Year: 2004
Induction of M. tuberculosis (MTB) drug resistance (DR) mutations in HIV-infected hosts and pathways of further spread of the evolutionary successful drug-resistant MTB clonal lines Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Relationship between exposure with drug resistant tuberculosis and developing new resistant cases Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
The first experience of therapeutic dendritic cells vaccine administration in patients with extensively drug resistant lung tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Central/effector memory T-cell dynamics in the peripheral blood of patients with active pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 10s Year: 2002
Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Expression of P-gP in patients with resistant tuberculosis Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012
Treatment outcome of multidrug resistant tuberculosis with second line drugs Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001
Evaluation of characteristics and treatment results of patients treated as multidrug resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
Improved tracking of nosocomial transmission of multidrug resistant M. tuberculosis with a novel T cell-based test Source: Eur Respir J 2003; 22: Suppl. 45, 167s Year: 2003
Role of mononuclear phagocytes in healing of experimental tuberculosis with multidrug resistance Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005
Multidrug resistant tuberculosis in non HIV patients Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
Frequency of development acquired drug resistance in successful treated patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 612s Year: 2002
Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011